Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Idea to Innovation

University of Toronto

$15,000.00

Market assessment for the commercialization of hydrogel for cell culture

EF 2024-25

Résumé
One of the obstacles limiting progress in the development of effective cancer therapies is the shortage of preclinical models. Patient-derived multicellular tumor organoids (PDOs) are a highly promising preclinical model that recapitulates the histology, gene expression, and drug response of the donor patient tumor. Currently, PDO culture relies on basement-membrane extract (BME, e.g. Matrigel), which suffers from batch-to-batch variability, the presence of xenogeneic compounds and residual growth factors, and poor control of mechanical properties. Additionally, for the development of new organoid lines from patient-derived xenografts, contamination of murine host cells poses problems. The PI has created a new biomimetic hydrogel, called EKGel. This hydrogel enables growth of breast cancer PDOs with histopathologic features, gene expression, and drug response that are similar to those of their parental tumors and PDOs in BME. In contrast to Matrigel, EKGel offers reduced batch-to-batch variability, a range of tunable mechanical properties, and suppressed contamination from murine cells. These results show that EKGel is an improved alternative to BME matrices for the initiation, growth, and maintenance of cancer PDOs. Furthermore, EKGel acts as a scaffold for different organoid types across diverse cancer types and permits accurate prediction of clinical response to diverse drug classes. EKGel combined with a microfluidic platform can revolutionize precision cancer care, addressing the industry's most pressing needs: improved treatment outcomes, reduced side effects, and accelerated drug discovery. By using patient-derived organoids, the EKGel Kit can mimic the complexity of human tumors, allowing for precise, real-time testing of drug responses in a patient's unique cancer microenvironment. This would enable oncologists to predict the most effective treatments, reducing the guesswork, minimizing side effects, and increasing the chances of treatment success. Funding is requested to undertake primary market research to better understand what end-users need to switch from Matrigel to EKGel Kit.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
602177-2025
Name nom
Kumacheva, Eugenia E
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2025
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1208
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Materials sciences
Area of application fr
Sciences des matériaux
Research subject code
2004
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Polymers and coatings
Research subject fr
Polymères et revêtements
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Market assessment for the commercialization of hydrogel for cell culture
Keywords
biomechanics; cell culture; cellulose nanocrystals; hydrogel; polymers
Application summary
One of the obstacles limiting progress in the development of effective cancer therapies is the shortage of preclinical models. Patient-derived multicellular tumor organoids (PDOs) are a highly promising preclinical model that recapitulates the histology, gene expression, and drug response of the donor patient tumor. Currently, PDO culture relies on basement-membrane extract (BME, e.g. Matrigel), which suffers from batch-to-batch variability, the presence of xenogeneic compounds and residual growth factors, and poor control of mechanical properties. Additionally, for the development of new organoid lines from patient-derived xenografts, contamination of murine host cells poses problems. The PI has created a new biomimetic hydrogel, called EKGel. This hydrogel enables growth of breast cancer PDOs with histopathologic features, gene expression, and drug response that are similar to those of their parental tumors and PDOs in BME. In contrast to Matrigel, EKGel offers reduced batch-to-batch variability, a range of tunable mechanical properties, and suppressed contamination from murine cells. These results show that EKGel is an improved alternative to BME matrices for the initiation, growth, and maintenance of cancer PDOs. Furthermore, EKGel acts as a scaffold for different organoid types across diverse cancer types and permits accurate prediction of clinical response to diverse drug classes. EKGel combined with a microfluidic platform can revolutionize precision cancer care, addressing the industry's most pressing needs: improved treatment outcomes, reduced side effects, and accelerated drug discovery. By using patient-derived organoids, the EKGel Kit can mimic the complexity of human tumors, allowing for precise, real-time testing of drug responses in a patient's unique cancer microenvironment. This would enable oncologists to predict the most effective treatments, reducing the guesswork, minimizing side effects, and increasing the chances of treatment success. Funding is requested to undertake primary market research to better understand what end-users need to switch from Matrigel to EKGel Kit.